Aeryana N. Beaudrie-Nunn, Pharm.D. (@ABeaudrieRx), identifies the rationale for immunodulatory therapy in COVID-19, explores clinical trial data regarding the use of Baricitinib in hospitalized patients with COVID-19, and defines the patient context where Baricitinib use is most appropriate. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.